Trial Profile
Phase III Clinical Study of JTE-052A - Randomized Controlled and Long-term Extension Study in Patients with Atopic Dermatitis -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Delgocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Japan Tobacco
- 03 Feb 2020 Results published in the Journal of the American Academy of Dermatology.
- 23 Jan 2020 According to an Japan Tobacco media release, the company announced that it has received manufacturing and marketing approval for CORECTIM Ointment 0.5% for an indication of atopic dermatitis in Japan.
- 01 Feb 2019 According to a Japan Tobacco media release, the company has filed a New Drug Application for JTE-052 ointment for atopic dermatitis.